SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is seeing intense volatility and aggressive liquidation as market participants debate its role as a safe-haven asset amidst escalating geopolitical tensions and energy sector disruptions. The community is actively discussing a decoupling from traditional hedges, with sentiment sharply divided between those viewing the decline as a major capitulation and buying opportunity and those interpreting the price action as a fundamental breakdown of the gold-as-a-hedge thesis.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors pile into the stock, fueled by intense geopolitical tensions and critical infrastructure damage in the Middle East that has tightened global LNG supply. The community is actively discussing the stock's parabolic volume and momentum, with many traders debating the sustainability of the rally and the potential for a short squeeze as supply-side concerns persist.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened volatility and trader attention as the market anticipates upcoming earnings and potential M&A catalysts. Investors remain intensely divided, with vocal debates continuing over market maker price manipulation, the CEOs compensation proposal, and the potential for a renewed short squeeze.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending after the unsealing of a federal indictment charging former employees and a co-founder with orchestrating an elaborate scheme to divert restricted hardware to China through shell companies. While the community is deeply divided between those viewing the company as a victim of internal deception that is now oversold, and those fearing long-term reputational damage, delisting risks, and client defections to competitors, traders are actively debating whether this represents a fundamental collapse or a massive, sentiment-driven buying opportunity.

Two Harbors Investment Corp. is a real estate investment trust, which invests in finances, and manages agency residential mortgage-backed securities, mortgage servicing rights, and other financial assets. The company was founded on May 21, 2009 and is headquartered in St. Louis Park, MN.

Two Harbors Investment Corp

Two Harbors Investment Corp. is trending due to an unsolicited all-cash acquisition offer of $10.70 per share, prompting an active community debate over whether the bid represents a superior proposal compared to the existing UWM Holdings merger agreement. Investors are closely analyzing the offer against the company's underlying book value and debating the likelihood of a higher counter-offer amid ongoing market volatility.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is facing extreme volatility and a sharp downward slide as investors grapple with massive price swings, liquidations, and heightened anxiety over the sustainability of recent rallies. The community is actively debating whether this is a structural market reset driven by technical manipulation and shifting institutional flows, or a temporary cooling period for a commodity previously inflated by aggressive sentiment.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors weigh its critical role as a supplier of indium phosphide substrates for AI data center optical connectivity against ongoing operational risks and volatile stock performance. While the community remains divided over the company's valuation and potential for further equity dilution, active discussions center on whether its technological relevance in the AI infrastructure supply chain outweighs persistent challenges related to opaque Chinese export permit requirements and unpredictable geopolitical supply chain hurdles.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing intense selling pressure and high volatility, with the community actively debating whether the current drop represents a generational buying opportunity or a deeper correction toward support levels near 50-60 dollars. Traders are largely attributing the decline to a broader liquidity crisis, rising yields, and a stronger dollar, while long-term investors emphasize physical silver demand and industrial shortages as reasons to hold despite the current market bloodbath.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is trending following reports that the government-sponsored entities have begun placing sizable orders for mortgage-backed securities to stabilize market volatility. While investors are debating the long-term implications of potential privatization and the influence of high-profile backers like Bill Ackman and Michael Burry, the community remains divided between those viewing the current price action as a strategic buying opportunity and those frustrated by the lack of definitive progress toward an exit from conservatorship.

Tria is a self-custodial neobank and cross-chain payments infrastructure designed to make onchain money usable in everyday life. It combines card spending, trading, and earning in a single account experience, so users can move value across chains without manually bridging assets, switching networks, or managing chain-specific steps. Under the hood, Tria routes every action through BestPath, an ultra-fast routing and execution layer that takes an intent like “spend,” “swap,” “send,” or “earn” and completes it end-to-end on the optimal path. Tria operates in two modes: a consumer app that includes a Visa-powered card, spot swaps, perpetual futures, and Earn vaults, and a developer and institutional layer that integrates with protocols and ecosystems to embed Tria’s execution rails wherever value already moves. The end goal is simple: one continuous flow for money across chains, with self-custody by default and a product experience that feels effortless for normal users worldwide.

TRIA

TRIA is gaining momentum as investors highlight its profitability, growing transaction volumes, and the utility of its self-custodial neobank platform. The community is actively discussing anticipation for upcoming major banking partnerships and new exchange listings as key catalysts for continued growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) saw a significant decrease in short interest in February. As of February 27th, there was short interest totaling 489,206 shares, a decrease...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - What's Next...

MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Down 6.6% - Time to Sell...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...

Shares of Mira Pharmaceuticals surged 70% after-hours on Wednesday after the company announced new preclinical data showing its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in an animal model of chronic inflammatory pain.The study, conducted as part of Mira’s Mira-55 program, found that the orally administered compound not only restored pain thresholds to baseline levels but also demonstrated strong anti-inflammatory effects, pointing to a dual action that morphine failed to match.&nbsp;The company said these findings will support its planned Investigational New Drug (IND) application for chronic inflammatory pain and reinforce its position in the $70 billion non-opioid pain market.Mira-55, a non-psychotropic marijuana analog, achieved full pain normalization and significantly reduced paw swelling, confirming a CB2 receptor-mediated anti-inflammatory mechanism. Morphine, by contrast, showed only partial inflammation reduction through indirect effects on the central nervous system.The company noted that this is the first study in the program to measure inflammation directly alongside pain. The oral efficacy of Mira-55 also offers clinical convenience compared with morphine, which requires injection to achieve similar pain control.On Stocktwits, retail sentiment for Mira was ‘extremely bullish’ amid a 7,000% surge in 24-hour message volume.One user on Stocktwits called it “absolutely insane” that a small biotech like Mira could claim Mira-55 outperforms morphine, saying it could draw major investors and even qualify for FDA fast-track review. The user highlighted that Mira-55’s oral delivery and CB2 receptor action were unheard of, adding that the $60 billion+ market gives the stock huge upside potential.&nbsp;<stembedurl>https://stocktwits.com/Moobumples/message/632515002</stembedurl>Another user said he sees potential in Mira-55 becoming a “blockbuster drug” and urged others to buy.<stembedurl>https://stocktwits.com/Intradaytrade100/message/632498480</stembedurl><a href="https://stocktwits.com/symbol/MIRA">Mira Pharmaceuticals’ stock</a> has risen 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharmaceuticals’ stock (MIRA) has risen 16% so far in 2025. (Photo credit: Getty Images)

Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making

The company said its oral treatment fully normalized pain and sharply reduced inflammation in preclinical studies, outperforming injected morphine. 

Equity

MIRA Pharmaceuticals Inc saw its shares rise to the highest levels in nearly two months after the clinical-stage pharmaceutical company announced the board’s approval of its planned acquisition of SKNY Pharmaceuticals Inc, a deal valued at over $60 million.The acquisition, which still requires approval from MIRA and SKNY’s shareholders, has been valued based on third-party analysis conducted by Moore Financial Consulting.&nbsp;SKNY Pharmaceuticals has an enterprise value of approximately $30.5 million, while MIRA's value stands at $30 million, bringing the combined enterprise value to over $60 million.Shares of MIRA Pharmaceuticals have gained 8.7% year-to-date, closing at $1.25 on Thursday, before dipping 6.4% in after-hours trading.MIRA CEO Erez Aminov emphasized that the merger combines two robust pipelines and a unified strategy, with a focus on developing therapies for obesity and nicotine dependence.&nbsp;Under the terms of the merger, SKNY is required to hold at least $5 million in cash or other assets to be transferred at closing.&nbsp;MIRA is preparing to file with the U.S. Securities and Exchange Commission to seek shareholder approval for the deal.SKNY Pharmaceuticals’ lead compound, SKNY-1, is being developed as a next-generation oral therapeutic targeting CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B), which plays a key role in dopamine metabolism and addiction regulation.&nbsp;The compound is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, with applications in two high-value therapeutic areas.MIRA’s leadership views the addition of SKNY-1 to its pipeline as a key step in positioning the company to capitalize on these growing markets. Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, Itzchak Angel, said the pharmacological profile of SKNY-1 could make it an effective treatment for both addiction and metabolic disorders.&nbsp;Early data from the compound’s development has been promising, according to Angel.On Stocktwits, sentiment was described as 'bullish' amid a 1,350% surge in 24-hour message volume.&nbsp;One user noted that the merger would be a significant win, expressing confidence that shareholders from both companies would approve, while another shared frustration over a pre-market entry at $1.70, followed by an immediate pullback.<stembedurl>https://stocktwits.com/BearTamerTrading/message/613998754</stembedurl><stembedurl>https://stocktwits.com/Kc24mo/message/613981879</stembedurl>The stock has risen 8.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong

Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading.

Shares of Mira Pharmaceuticals&nbsp;gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MIRA_sentiment_and_message_volume_as_of_April_16_png_9320cb3838.webp" alt="MIRA sentiment and message volume as of April 16.png" width="1318" height="316"><figcaption>MIRA sentiment and message volume as of April 16. | source: Stocktwits</figcaption></figure>One watcher expects the stock to cross the $1.2 mark on Thursday easily.<stembedurl>https://stocktwits.com/BadBritt/message/611883890</stembedurl>Another said a new 52-week high was imminent.<stembedurl>https://stocktwits.com/HMIC/message/611835137</stembedurl>Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025.&nbsp;A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026.&nbsp;Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

MIRA
Mira Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MIRA News

MIRAMira Pharmaceuticals Inc